Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of ZG006 combined with ZG005 in advanced small cell lung cancer or neuroendocrine carcinoma
CTR20252382Phase 2Active
- Sponsor
- Zelgen
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig, nilvanstomig in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), sponsored by Zelgen. Started Sep 2025; status: active.
02
Drugs
alveltamignilvanstomig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20252382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252382.